FDA
Biotech

FDA outlines draft policy on MRD for accelerated approval

The guidance provides recommendations for designing clinical trials that use MRD or CR as endpoints for accelerated approval in multiple myeloma.
Angus Liu Jan 21, 2026 2:55pm
Albert Bourla
Favicon Fierce Pharma

Pfizer CEO blasts RFK Jr. over 'anti-science' vaccine stance: WSJ

Jan 21, 2026 11:01am
ExamOne executive details how mobile phlebotomy is reshaping clinical research

ExamOne executive details how mobile phlebotomy is reshaping clinical research

Jan 19, 2026 8:00am
Evans

Inside Beam's 'big push' for in vivo gene editing

Jan 21, 2026 7:52am
FDA Grants RMAT Designation to iRegenes NouvNeu001 Cementing its Lead as the Worlds First iPSC Therapy with Both FTD a

iRegene Secures Historic FDA RMAT for Parkinson’s iPSC Therapy

Jan 19, 2026 8:00am
relay

Novo hands diabetes assets to Aspect amid cell therapy retreat

Jan 21, 2026 10:13am
More News

Fierce Biotech Fundraising Tracker 2026: Think Bio & more

Jan 21, 2026 9:30am

Cancer imaging company buys Lisata for ph. 2-stage tumor drug

Jan 21, 2026 9:20am

IO mulls more layoffs months after halving head count

Jan 21, 2026 7:20am

Insilico agrees to $66M deal to split rights for NLRP3 inhibitor

Jan 21, 2026 7:05am